CD4 peptides for binding to viral envelope proteins
US5603933A · kind A · utility
15Cited by
13References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 31, 1993 |
| Grant date | Feb 18, 1997 |
| Priority date | — |
| Expiry date | Aug 31, 2013 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compositions and methods for use in viral binding and inactivation and in protecting cells from viral infection, particularly, for use in protecting target human CD4.sup.+ cells from infection by HIV. Peptides including short sequences from CD4 are identified as being particularly effective at binding to gp120 and inhibiting or reducing HIV infection of human CD4.sup.+ cells by steric hinderance or catalytic inactivation of gp120. The invention thus encompasses improved CD4-based peptide compositions and therapeutic formulations with viral binding and HIV-inhibitory activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.